AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19743725 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-step acne system (salicylic acid cleanser 2% twice daily, salicylic acid toner 2% once daily, solubilized BPO gel 5% twice daily)
Number of subjects: 139
Study 19743725 — intervention group
Group type: COMPARATOR
Intervention: Control (cleanser twice daily plus clindamycin 1%-BPO 5% gel twice daily)
Number of subjects: 139
Study 19743725 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 139
Study 17407459 — intervention group
Group type: EXPERIMENTAL
Intervention: Early exposure to an odorant for 30 min beginning 4-37 min after birth
Number of subjects: 55
Study 17407459 — intervention group
Group type: EXPERIMENTAL
Intervention: Late exposure to an odorant for 30 min beginning 12 hours post-partum
Number of subjects: 55
Study 15209304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyrical Music
Number of subjects: 57
Study 15209304 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental Music
Number of subjects: 57
Study 15209304 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking
Number of subjects: 57
Study 15209304 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study 11192885 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency tissue volume reduction (RFTVR)
Number of subjects: 24
Study 11192885 — intervention group
Group type: COMPARATOR
Intervention: Laser vaporizing turbinoplasty (LVT)
Number of subjects: 24
Study 11042828 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG injection followed by oocyte retrieval at 34 hours (group A)
Number of subjects: 170
Study 11042828 — intervention group
Group type: COMPARATOR
Intervention: hCG injection followed by oocyte retrieval at 38 hours (group B)
Number of subjects: 170
Study 8957645 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoic acid (2 concentrations)
Number of subjects: 200
Study 8957645 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-cinnamic acid (2 concentrations)
Number of subjects: 200
Study 8957645 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl nicotinate (2 concentrations)
Number of subjects: 200
Study 8957645 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 200
Study 8957645 — intervention group
Group type: COMPARATOR
Intervention: General observation
Number of subjects: 200
Study 1416127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (10 micrograms)
Number of subjects: 65
Study 1416127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine (10 mg)
Number of subjects: 65
Study 1416127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (5 micrograms)
Number of subjects: 65
Study 3912695 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover regime: adriamycin (40 mg/m2 day 1), cisplatin (100 mg/m2 day 2), vincristine (1.4 mg/m2 day 28), cyclophosphamide (1,500 mg/m2 day 25), methotrexate (1,000 mg/m2 day 56) (2 cycles)
Number of subjects: 150
Study 3912695 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (40 mg/m2) and cyclophosphamide (500 mg/m2)
Number of subjects: 150
Study 3912695 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (40 mg/m2) and cisplatin (50 mg/m2)
Number of subjects: 150
Study 3912695 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover regime for patients with highly differentiated tumors
Number of subjects: 150
Study 3912695 — intervention group
Group type: COMPARATOR
Intervention: Other regimens for patients with less differentiated tumors
Number of subjects: 150
Study 31117967 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin regimen (30-40 mg/m2 on days 1, 8, 15, 22, 29, 36, and 43)
Number of subjects: 322
Study 31117967 — intervention group
Group type: COMPARATOR
Intervention: Triweekly cisplatin regimen (80-100 mg/m2 on days 1, 22, and 43)
Number of subjects: 322
Study 31117967 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin regimen
Number of subjects: 322
Study 31117967 — intervention group
Group type: COMPARATOR
Intervention: Triweekly cisplatin regimen
Number of subjects: 322
Study 28544397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity microdroplet device
Number of subjects: 60
Study 28544397 — intervention group
Group type: COMPARATOR
Intervention: Dental floss
Number of subjects: 60
Study 28544397 — intervention group
Group type: COMPARATOR
Intervention: High-velocity microdroplet device and Dental floss
Number of subjects: 60
Study 26041583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic nutrition recommendations (NNR diet)
Number of subjects: 12
Study 26041583 — intervention group
Group type: COMPARATOR
Intervention: Palaeolithic diet (PD)
Number of subjects: 12
Study 24861492 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DL‐PDT)
Number of subjects: 100
Study 24861492 — intervention group
Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (c‐PDT)
Number of subjects: 100
Study 22648722 — intervention group
Group type: COMPARATOR
Intervention: B vitamins (0.56 mg 5-methyl-tetrahydrofolate, 3 mg B-6, 0.02 mg B-12)
Number of subjects: 2501
Study 22648722 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA and DHA 600 mg in a 2:1 ratio)
Number of subjects: 2501
Study 22648722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2501
Study 20200382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 1679
Study 20200382 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 1679
Study 20200382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (in cardiogenic shock)
Number of subjects: 1679
Study 20200382 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (in cardiogenic shock)
Number of subjects: 1679
Study 20200382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (in septic shock)
Number of subjects: 1679
Study 20200382 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (in septic shock)
Number of subjects: 1679
Study 20200382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (in hypovolemic shock)
Number of subjects: 1679
Study 20200382 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (in hypovolemic shock)
Number of subjects: 1679
Study 18056580 — intervention group
Group type: EXPERIMENTAL
Intervention: PD‐PCP in 'off' condition
Number of subjects: 27
Study 18056580 — intervention group
Group type: COMPARATOR
Intervention: PD‐NoP in 'off' condition
Number of subjects: 27
Study 18056580 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects in 'off' condition
Number of subjects: 27
Study 18056580 — intervention group
Group type: EXPERIMENTAL
Intervention: PD‐PCP in 'on' condition
Number of subjects: 27
Study 18056580 — intervention group
Group type: COMPARATOR
Intervention: PD‐NoP in 'on' condition
Number of subjects: 27
Study 18056580 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects in 'on' condition
Number of subjects: 27
Study 16142802 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab during PTCA (group 1, 70 patients)
Number of subjects: 140
Study 16142802 — intervention group
Group type: COMPARATOR
Intervention: conventional treatment without GP IIb/IIIa inhibitor (group 2, 70 patients)
Number of subjects: 140
Study 12141722 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 15
Study 12141722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10447220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifibrol therapy
Number of subjects: 4
Study 10447220 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin therapy
Number of subjects: 4
Study 7823387 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate allocation concealment
Number of subjects: 250
Study 7823387 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclear allocation concealment
Number of subjects: 250
Study 7823387 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusions after randomization
Number of subjects: 250
Study 7823387 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-double-blind trials
Number of subjects: 250
Study 2276311 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol-treated eyes
Number of subjects: 21
Study 2276311 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated eyes
Number of subjects: 21
Study 2276311 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 31631472 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp (WA) group
Number of subjects: 74
Study 31631472 — intervention group
Group type: COMPARATOR
Intervention: Electronic mail (eM) group
Number of subjects: 74
Study 30888751 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM plus Adefovir (ADV)
Number of subjects: 30
Study 30888751 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (ETV) monotherapy
Number of subjects: 30
Study 28126349 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-spectrum endoscopy (FUSE)
Number of subjects: 52
Study 28126349 — intervention group
Group type: COMPARATOR
Intervention: Conventional forward-viewing colonoscopy (FVC)
Number of subjects: 52
Study 28126349 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted tissue acquisition
Number of subjects: 52
Study 25772684 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial sealant (InteguSeal© Kimberly‐Clark)
Number of subjects: 100
Study 25772684 — intervention group
Group type: COMPARATOR
Intervention: No microbial sealant (control)
Number of subjects: 100
Study 25772684 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 100
Study 23085970 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity-based training (VEL)
Number of subjects: 32
Study 23085970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-based training (INT)
Number of subjects: 32
Study 21402601 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended callback counselling (4 to 6 calls delivered 1-3 months after quitting)
Number of subjects: 698
Study 21402601 — intervention group
Group type: COMPARATOR
Intervention: Usual care (4 calls in the first month after quitting)
Number of subjects: 698
Study 17602098 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year television/radio campaign aimed at adolescent smoking cessation
Number of subjects: 2030
Study 17602098 — intervention group
Group type: COMPARATOR
Intervention: No media campaign (comparison group)
Number of subjects: 2030
Study 17207299 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg 6 hourly for 7 days plus continuous wound infusion of ropivacaine 0.75% for 30 h
Number of subjects: 60
Study 17207299 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules identical to those of gabapentin for 7 days and continuous wound infusion of normal saline for 30 h
Number of subjects: 60
Study 17207299 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin and ropivacaine treatment
Number of subjects: 60
Study 15494620 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based home assessment
Number of subjects: 200
Study 15494620 — intervention group
Group type: COMPARATOR
Intervention: Home visit
Number of subjects: 200
Study 12575605 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) therapy for relieving blood stasis, invigorating Spleen and soothing Liver, administered for 5-6 weeks
Number of subjects: 120
Study 12575605 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 9127390 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI pacing at a rate of 60 beats/min
Number of subjects: 20
Study 8161954 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus of water ingested 2 hours before induction of anesthesia
Number of subjects: 0
Study 8161954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no water bolus)
Number of subjects: 0
Study 2894911 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 50 mg X 2
Number of subjects: 32
Study 2894911 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg X 2
Number of subjects: 32
Study 2894911 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol 80 mg X 2
Number of subjects: 32
Study 2894911 — intervention group
Group type: COMPARATOR
Intervention: placebo X 2
Number of subjects: 32
Study 31858696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Pharmacist intervention for 6 months
Number of subjects: 55
Study 31858696 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Usual care
Number of subjects: 55
Study 31096654 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective aluminum CFI (60 HB Brinell hardness)
Number of subjects: 0
Study 31096654 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene CFI (58° Shore D)
Number of subjects: 0
Study 31096654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethylene vinyl acetate CFI (EVA) (52° Shore A)
Number of subjects: 0
Study 31096654 — intervention group
Group type: COMPARATOR
Intervention: Standard EVA (25° Shore A)
Number of subjects: 0
Study 28056933 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVEdiabetes programme (intervention)
Number of subjects: 154
Study 28056933 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 154
Study 25592254 — intervention group
Group type: EXPERIMENTAL
Intervention: amodiaquine‐artesunate (AQ‐AS)
Number of subjects: 0
Study 25592254 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin‐piperaquine (DHA‐PQ)
Number of subjects: 0
Study 25592254 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether‐lumefantrine (AL)
Number of subjects: 0
Study 25592254 — intervention group
Group type: EXPERIMENTAL
Intervention: mefloquine‐artesunate (MQAS)
Number of subjects: 0
Study 25592254 — intervention group
Group type: COMPARATOR
Intervention: All treatments (AQ‐AS, DHA‐PQ, AL, MQAS)
Number of subjects: 0
Study 24018227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile eye-tracking procedure
Number of subjects: 0
Study 21533301 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC petroleum-based skin protectant moisturizer (OTC-Pet, Aquaphor Healing Ointment®)
Number of subjects: 39
Study 21533301 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid-containing barrier repair cream (BRC-Gly, Atopiclair®)
Number of subjects: 39
Study 21533301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-dominant barrier repair cream (BRC-Cer, EpiCeram®)
Number of subjects: 39
Study 21533301 — intervention group
Group type: COMPARATOR
Intervention: BRC-Gly, BRC-Cer
Number of subjects: 39
Study 18096281 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention delivered by trained nurses; duration between 5 and 65 minutes.
Number of subjects: 195
Study 17062450 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality group
Number of subjects: 122
Study 17062450 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Support group
Number of subjects: 122
Study 17062450 — intervention group
Group type: COMPARATOR
Intervention: Emotional Support group
Number of subjects: 122
Study 14633817 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 133
Study 14633817 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 133
Study 14633817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 11147601 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 6467
Study 11147601 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 6467
Study 8602315 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% buffered lidocaine
Number of subjects: 52
Study 8602315 — intervention group
Group type: COMPARATOR
Intervention: Bacteriostatic saline
Number of subjects: 52
Study 10146979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clentiazem (calcium channel blocker)
Number of subjects: 88
Study 10146979 — intervention group
Group type: COMPARATOR
Intervention: Symptom checklist
Number of subjects: 88
Study 10146979 — intervention group
Group type: COMPARATOR
Intervention: Open-ended question method
Number of subjects: 88
Study 10146979 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life measures
Number of subjects: 88
Study 2934438 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2‐interferon injected three times a week
Number of subjects: 12
Study 2934438 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) injected three times a week
Number of subjects: 12
Study 2934438 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo ointment
Number of subjects: 12
Study 2934438 — intervention group
Group type: COMPARATOR
Intervention: Topical betamethasone ointment
Number of subjects: 12
Study 30052277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark triad personality (DTP) traits, specifically Machiavellianism
Number of subjects: 168
Study 30052277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediators (organizational commitment and organizational justice)
Number of subjects: 168
Study 30052277 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological contract breach
Number of subjects: 168
Study 28256397 — intervention group
Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 17
Study 28256397 — intervention group
Group type: EXPERIMENTAL
Intervention: Static-dynamic stretching protocol
Number of subjects: 17
Study 26645922 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bandage wrap applied to leg for 8 hours
Number of subjects: 24
Study 26645922 — intervention group
Group type: COMPARATOR
Intervention: Unwrapped leg (control)
Number of subjects: 24
Study 23621432 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 cholangiogram
Number of subjects: 36
Study 23621432 — intervention group
Group type: COMPARATOR
Intervention: Iodine contrast (control group)
Number of subjects: 36
Study 22030947 — intervention group
Group type: COMPARATOR
Intervention: 250 mg caffeine (C)
Number of subjects: 10
Study 22030947 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg geranamine (G 50 mg)
Number of subjects: 10
Study 22030947 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg geranamine (G 75 mg)
Number of subjects: 10
Study 22030947 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg caffeine + 50 mg geranamine (C + G 50 mg)
Number of subjects: 10
Study 22030947 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg caffeine + 75 mg geranamine (C + G 75 mg)
Number of subjects: 10
Study 18465339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation (OA)
Number of subjects: 1628
Study 18465339 — intervention group
Group type: COMPARATOR
Intervention: Nine courses of three-weekly cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
Number of subjects: 1628
Study 16132165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg once daily
Number of subjects: 1600
Study 16132165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily
Number of subjects: 1600
Study 16132165 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 1600
Study 16132165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1600
Study 15557380 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 145
Study 15557380 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 145
Study 11756615 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g acetaminophen daily (n = 20)
Number of subjects: 42
Study 11756615 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (n = 22)
Number of subjects: 42
Study 9314634 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes team intervention (diabetes nurse educator and endocrinologist)
Number of subjects: 179
Study 9314634 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 179
Study 9314634 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes team intervention
Number of subjects: 179
Study 8338289 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐CY (pulse cyclophosphamide 0.5 to 1.0 g/m2 body surface area monthly for 7 doses)
Number of subjects: 39
Study 8338289 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐CY (pulse cyclophosphamide 0.5 to 1.0 g/m2 body surface area monthly for 15 or more doses)
Number of subjects: 39
Study 8338289 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐CY
Number of subjects: 39
Study 8338289 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐CY vs Long‐CY (age > 25 years)
Number of subjects: 39
Study 8338289 — intervention group
Group type: COMPARATOR
Intervention: Control (methylprednisolone 1.0 g/m2 monthly for 9 doses)
Number of subjects: 39
Study 3551577 — intervention group
Group type: EXPERIMENTAL
Intervention: Copovithane schedule A: 6 g/m2 i.v. over 30 min daily for 5 consecutive days and repeated every 3 weeks
Number of subjects: 30
Study 3551577 — intervention group
Group type: EXPERIMENTAL
Intervention: Copovithane schedule B: 10 g/m2 i.v. over 30 min once a week until progression, unacceptable toxicity, or up to 18 months
Number of subjects: 30
Study 29557290 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face (F2F)
Number of subjects: 12
Study 29557290 — intervention group
Group type: COMPARATOR
Intervention: e-guidance (EC)
Number of subjects: 12
Study 26803086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led motivational interviewing
Number of subjects: 30
Study 26803086 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge care (Control)
Number of subjects: 30
Study 24805184 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 0
Study 24805184 — intervention group
Group type: COMPARATOR
Intervention: boosted lopinavir
Number of subjects: 0
Study 24805184 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (general)
Number of subjects: 0
Study 23111127 — intervention group
Group type: EXPERIMENTAL
Intervention: Website intervention (n = 6055)
Number of subjects: 12287
Study 23111127 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group (n = 6232)
Number of subjects: 12287
Study 20554978 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 2292
Study 20554978 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent
Number of subjects: 2292